KR101989203B1 - 피라졸 화합물 및 그의 의약 용도 - Google Patents
피라졸 화합물 및 그의 의약 용도 Download PDFInfo
- Publication number
- KR101989203B1 KR101989203B1 KR1020147004780A KR20147004780A KR101989203B1 KR 101989203 B1 KR101989203 B1 KR 101989203B1 KR 1020147004780 A KR1020147004780 A KR 1020147004780A KR 20147004780 A KR20147004780 A KR 20147004780A KR 101989203 B1 KR101989203 B1 KR 101989203B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- alkyl group
- compound
- alkoxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C*(C)C(CNC(C)=O)C(Nc1n[n](*)c(-c2cc(*)ccc2)c1)=O Chemical compound C*C*(C)C(CNC(C)=O)C(Nc1n[n](*)c(-c2cc(*)ccc2)c1)=O 0.000 description 5
- ZPCJPJQUVRIILS-UHFFFAOYSA-N BrCc1cccc(Br)c1 Chemical compound BrCc1cccc(Br)c1 ZPCJPJQUVRIILS-UHFFFAOYSA-N 0.000 description 1
- RTGUJFWBQLNZDR-UHFFFAOYSA-N CC(C(CN1)C(O)=O)C1=O Chemical compound CC(C(CN1)C(O)=O)C1=O RTGUJFWBQLNZDR-UHFFFAOYSA-N 0.000 description 1
- VSOVNOQGBJKJRM-PBVYKCSPSA-N CC(C)(C(F)(F)F)OCc1cc(Cl)cc(C2=CC(NC([C@@H](C3)CNC3=O)=O)NN2c2ccccc2)c1 Chemical compound CC(C)(C(F)(F)F)OCc1cc(Cl)cc(C2=CC(NC([C@@H](C3)CNC3=O)=O)NN2c2ccccc2)c1 VSOVNOQGBJKJRM-PBVYKCSPSA-N 0.000 description 1
- UDZLUXXCXDIIOK-MRVPVSSYSA-N CC(C)(C)OC(NC[C@H](C(O)=O)NC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)OC(NC[C@H](C(O)=O)NC(OC(C)(C)C)=O)=O UDZLUXXCXDIIOK-MRVPVSSYSA-N 0.000 description 1
- AQMGGDNUPCUVKT-GKAPJAKFSA-N CC(CC=C)N(C)[C@@H]1NNC=C1 Chemical compound CC(CC=C)N(C)[C@@H]1NNC=C1 AQMGGDNUPCUVKT-GKAPJAKFSA-N 0.000 description 1
- WLVSTXWBNDJBBG-UHFFFAOYSA-N CCCCc1cccc(Br)c1 Chemical compound CCCCc1cccc(Br)c1 WLVSTXWBNDJBBG-UHFFFAOYSA-N 0.000 description 1
- DTUQWUYSSXSHMX-WTUNAVPPSA-N CC[C@@H]([C@@H](CN1)C(N([C@H](CC2C=CC=CC2)CO2)C2=O)=O)C1=O Chemical compound CC[C@@H]([C@@H](CN1)C(N([C@H](CC2C=CC=CC2)CO2)C2=O)=O)C1=O DTUQWUYSSXSHMX-WTUNAVPPSA-N 0.000 description 1
- MEUCEHRBIIEAFJ-UHFFFAOYSA-N COC(C1(CC1)C(OS(C(F)(F)F)(=O)=O)=C)=O Chemical compound COC(C1(CC1)C(OS(C(F)(F)F)(=O)=O)=C)=O MEUCEHRBIIEAFJ-UHFFFAOYSA-N 0.000 description 1
- MFIDBOPLJVYDCO-GICMACPYSA-N C[C@@H](OCC(CC(C)=C1)C=C1c1cc(N)n[n]1C1=CC=CCC1)[F]C(F)F Chemical compound C[C@@H](OCC(CC(C)=C1)C=C1c1cc(N)n[n]1C1=CC=CCC1)[F]C(F)F MFIDBOPLJVYDCO-GICMACPYSA-N 0.000 description 1
- XYXPCKFHJQTDJA-RLQYFTDUSA-N C[C@@H]1N(C(/C=C\N[IH](/C=C\C)=CC=C)NC)C(C)=CC1 Chemical compound C[C@@H]1N(C(/C=C\N[IH](/C=C\C)=CC=C)NC)C(C)=CC1 XYXPCKFHJQTDJA-RLQYFTDUSA-N 0.000 description 1
- QJYBFKDHLUMYMI-SNVBAGLBSA-N C[C@H](C(F)(F)F)OCc1cc(F)cc(B2OC(C)(C)C(C)(C)O2)c1 Chemical compound C[C@H](C(F)(F)F)OCc1cc(F)cc(B2OC(C)(C)C(C)(C)O2)c1 QJYBFKDHLUMYMI-SNVBAGLBSA-N 0.000 description 1
- VZTHIUBPUTUJCD-SSDOTTSWSA-N C[C@H](C(F)(F)F)OCc1cccc(F)c1 Chemical compound C[C@H](C(F)(F)F)OCc1cccc(F)c1 VZTHIUBPUTUJCD-SSDOTTSWSA-N 0.000 description 1
- UZNPLOZMSCYGHQ-AFPNSQJFSA-N C[C@H](CC(O)[O-]C)C(CBr)C(OC)OC Chemical compound C[C@H](CC(O)[O-]C)C(CBr)C(OC)OC UZNPLOZMSCYGHQ-AFPNSQJFSA-N 0.000 description 1
- OJABSIHAAXMDGK-ZYHUDNBSSA-N C[C@H]([C@H](CN1Cc(ccc(OC)c2)c2OC)C=O)C1=O Chemical compound C[C@H]([C@H](CN1Cc(ccc(OC)c2)c2OC)C=O)C1=O OJABSIHAAXMDGK-ZYHUDNBSSA-N 0.000 description 1
- QZSKJRJSYCBEJH-UHFFFAOYSA-N Cc1ccc(C)[n]1C(C=C1I)NN1c(cc1)ccc1F Chemical compound Cc1ccc(C)[n]1C(C=C1I)NN1c(cc1)ccc1F QZSKJRJSYCBEJH-UHFFFAOYSA-N 0.000 description 1
- RVYOBWJBYDVZSM-UHFFFAOYSA-N Cc1ccc(C)[n]1C(C=C1I)NN1c(cccc1)c1F Chemical compound Cc1ccc(C)[n]1C(C=C1I)NN1c(cccc1)c1F RVYOBWJBYDVZSM-UHFFFAOYSA-N 0.000 description 1
- DMMCFHVQUWBMSI-UHFFFAOYSA-N NC(C=C1I)NN1c(cc1)ccc1F Chemical compound NC(C=C1I)NN1c(cc1)ccc1F DMMCFHVQUWBMSI-UHFFFAOYSA-N 0.000 description 1
- DNXHAUJMJJAIHA-UHFFFAOYSA-N NC(C=C1I)NN1c(cccc1)c1F Chemical compound NC(C=C1I)NN1c(cccc1)c1F DNXHAUJMJJAIHA-UHFFFAOYSA-N 0.000 description 1
- DEMYZMRYBCTGRY-UHFFFAOYSA-N NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1F Chemical compound NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1F DEMYZMRYBCTGRY-UHFFFAOYSA-N 0.000 description 1
- JIYFLEINWZNTST-UHFFFAOYSA-N NC(CC1c2cc(OC(F)(F)F)ccc2)=NN1c(cc1)ccc1F Chemical compound NC(CC1c2cc(OC(F)(F)F)ccc2)=NN1c(cc1)ccc1F JIYFLEINWZNTST-UHFFFAOYSA-N 0.000 description 1
- DYYSREGJCZINTF-UHFFFAOYSA-N Nc(cc1-c2cc(OC(F)(F)F)ccc2)n[n]1-c(cc1)ccc1F Chemical compound Nc(cc1-c2cc(OC(F)(F)F)ccc2)n[n]1-c(cc1)ccc1F DYYSREGJCZINTF-UHFFFAOYSA-N 0.000 description 1
- OWQALAQIMKHUIH-OOJLDXBWSA-N O=C([C@@H](C1)CNC1=O)NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1F Chemical compound O=C([C@@H](C1)CNC1=O)NC(C=C1c2cc(COCC(F)(F)F)cc(F)c2)NN1c(cc1)ccc1F OWQALAQIMKHUIH-OOJLDXBWSA-N 0.000 description 1
- MBBCUMUIGBKUEC-UHFFFAOYSA-N OC(C(CO1)=CC1=O)=O Chemical compound OC(C(CO1)=CC1=O)=O MBBCUMUIGBKUEC-UHFFFAOYSA-N 0.000 description 1
- GZVHQYZRBCSHAI-VKHMYHEASA-N OC([C@@H](C1)CNC1=O)=O Chemical compound OC([C@@H](C1)CNC1=O)=O GZVHQYZRBCSHAI-VKHMYHEASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011188121 | 2011-08-31 | ||
| JPJP-P-2011-188121 | 2011-08-31 | ||
| US201161573433P | 2011-09-06 | 2011-09-06 | |
| US61/573,433 | 2011-09-06 | ||
| PCT/JP2012/072066 WO2013031922A1 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140062048A KR20140062048A (ko) | 2014-05-22 |
| KR101989203B1 true KR101989203B1 (ko) | 2019-06-13 |
Family
ID=47756400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147004780A Active KR101989203B1 (ko) | 2011-08-31 | 2012-08-30 | 피라졸 화합물 및 그의 의약 용도 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US8846746B2 (https=) |
| EP (4) | EP3524599A1 (https=) |
| JP (6) | JP6091811B2 (https=) |
| KR (1) | KR101989203B1 (https=) |
| CN (1) | CN103917535B (https=) |
| AR (2) | AR087701A1 (https=) |
| AU (1) | AU2012302723B2 (https=) |
| BR (1) | BR112014004651B1 (https=) |
| CA (1) | CA2845127C (https=) |
| CL (1) | CL2014000490A1 (https=) |
| CO (1) | CO6890098A2 (https=) |
| CY (1) | CY1121631T1 (https=) |
| DK (1) | DK3199533T3 (https=) |
| HK (1) | HK1202290A1 (https=) |
| IL (1) | IL230763A (https=) |
| MX (1) | MX359825B (https=) |
| MY (1) | MY172422A (https=) |
| PE (1) | PE20142343A1 (https=) |
| PH (1) | PH12014500444A1 (https=) |
| PL (1) | PL3199533T3 (https=) |
| RS (1) | RS58870B1 (https=) |
| RU (1) | RU2617678C2 (https=) |
| SG (1) | SG11201400244YA (https=) |
| SI (1) | SI3199533T1 (https=) |
| SM (1) | SMT201900292T1 (https=) |
| TW (1) | TWI549949B (https=) |
| WO (1) | WO2013031922A1 (https=) |
| ZA (1) | ZA201401071B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| JP5663699B2 (ja) | 2012-05-07 | 2015-02-04 | キッセイ薬品工業株式会社 | ピラゾール誘導体及びその医薬用途 |
| ES2646916T3 (es) | 2012-11-19 | 2017-12-18 | Bayer Pharma Aktiengesellschaft | Aminoimidazopiridazinas como inhibidores de MKNK1 cinasa |
| MY176162A (en) * | 2013-02-04 | 2020-07-24 | Taisho Pharmaceutical Co Ltd | Prophylactic or therapeutic drug for constipation |
| US9334307B2 (en) | 2013-05-08 | 2016-05-10 | The University Of Houston System | Targeting the EGFR-SGLT1 interaction for cancer therapy |
| CN105294703B (zh) * | 2015-10-23 | 2018-01-23 | 西安近代化学研究所 | 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法 |
| BR112019002733A2 (pt) | 2016-08-11 | 2019-05-14 | Bayer Cropscience Ag | derivados de pirazolinil substituídos, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta |
| JP6994498B2 (ja) | 2016-08-15 | 2022-02-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ３－アミノ－１－（２，６－二置換フェニル）ピラゾール類を調製する方法 |
| TWI805699B (zh) * | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
| EP3778593A4 (en) | 2018-04-04 | 2021-12-22 | Japan Tobacco Inc. | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE |
| JP7760370B2 (ja) * | 2019-09-04 | 2025-10-27 | 日本たばこ産業株式会社 | 慢性腎臓病の治療又は予防方法 |
| US20230119894A1 (en) * | 2019-09-04 | 2023-04-20 | Japan Tobacco Inc. | Therapeutic or prophylactic method for diabetes using combination medicine |
| CA3175131A1 (en) | 2020-03-19 | 2021-09-23 | Chihiro Okuma | Treatment or prevention method for chronic heart failure |
| WO2025249555A1 (en) * | 2024-05-31 | 2025-12-04 | Japan Tobacco Inc. | Method for treating or preventing hypertrophic cardiomyopathy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008285481A (ja) | 2007-04-20 | 2008-11-27 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
| US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| WO2001012189A1 (en) * | 1999-08-12 | 2001-02-22 | Pharmacia Italia S.P.A. | 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| RU2356906C2 (ru) * | 2002-08-08 | 2009-05-27 | Киссеи Фармасьютикал Ко., Лтд. | Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения |
| JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| DE102004028241B4 (de) * | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
| AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
| AP2007003979A0 (en) | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
| WO2007034279A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| TWI378922B (en) * | 2005-10-21 | 2012-12-11 | Mitsubishi Tanabe Pharma Corp | A pyrazole compound |
| JP5069894B2 (ja) * | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
| EP1951678A1 (en) | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| US20070117858A1 (en) * | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
| EP2079728B1 (en) * | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010222298A (ja) * | 2009-03-24 | 2010-10-07 | Shionogi & Co Ltd | Ｎｐｙｙ５受容体拮抗作用を有するピロリドン誘導体 |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| WO2012002527A1 (ja) | 2010-07-02 | 2012-01-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| WO2012080729A2 (en) | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
-
2012
- 2012-08-28 AR ARP120103173A patent/AR087701A1/es active IP Right Grant
- 2012-08-30 RS RS20190581A patent/RS58870B1/sr unknown
- 2012-08-30 AU AU2012302723A patent/AU2012302723B2/en active Active
- 2012-08-30 EP EP19159289.8A patent/EP3524599A1/en not_active Withdrawn
- 2012-08-30 EP EP17157922.0A patent/EP3199533B1/en active Active
- 2012-08-30 PH PH1/2014/500444A patent/PH12014500444A1/en unknown
- 2012-08-30 CN CN201280050398.9A patent/CN103917535B/zh active Active
- 2012-08-30 EP EP12827193.9A patent/EP2784074A4/en not_active Withdrawn
- 2012-08-30 WO PCT/JP2012/072066 patent/WO2013031922A1/ja not_active Ceased
- 2012-08-30 PL PL17157922T patent/PL3199533T3/pl unknown
- 2012-08-30 SM SM20190292T patent/SMT201900292T1/it unknown
- 2012-08-30 JP JP2012190429A patent/JP6091811B2/ja active Active
- 2012-08-30 SI SI201231595T patent/SI3199533T1/sl unknown
- 2012-08-30 EP EP25203401.2A patent/EP4656638A3/en active Pending
- 2012-08-30 TW TW101131507A patent/TWI549949B/zh active
- 2012-08-30 KR KR1020147004780A patent/KR101989203B1/ko active Active
- 2012-08-30 HK HK15102725.1A patent/HK1202290A1/en unknown
- 2012-08-30 PE PE2014001489A patent/PE20142343A1/es active IP Right Grant
- 2012-08-30 DK DK17157922.0T patent/DK3199533T3/da active
- 2012-08-30 RU RU2014112048A patent/RU2617678C2/ru active
- 2012-08-30 MY MYPI2014000387A patent/MY172422A/en unknown
- 2012-08-30 SG SG11201400244YA patent/SG11201400244YA/en unknown
- 2012-08-30 MX MX2014002552A patent/MX359825B/es active IP Right Grant
- 2012-08-30 CA CA2845127A patent/CA2845127C/en active Active
- 2012-08-30 BR BR112014004651-4A patent/BR112014004651B1/pt active IP Right Grant
- 2012-08-30 US US13/599,665 patent/US8846746B2/en active Active
-
2014
- 2014-02-02 IL IL230763A patent/IL230763A/en active IP Right Grant
- 2014-02-11 ZA ZA2014/01071A patent/ZA201401071B/en unknown
- 2014-02-25 CO CO14038962A patent/CO6890098A2/es active IP Right Grant
- 2014-02-27 CL CL2014000490A patent/CL2014000490A1/es unknown
- 2014-07-29 US US14/445,500 patent/US20150183763A1/en not_active Abandoned
-
2017
- 2017-02-08 JP JP2017021326A patent/JP2017082005A/ja not_active Ceased
- 2017-12-21 US US15/850,874 patent/US20180346449A1/en not_active Abandoned
-
2018
- 2018-05-02 JP JP2018088578A patent/JP2018115216A/ja not_active Ceased
-
2019
- 2019-05-08 CY CY20191100491T patent/CY1121631T1/el unknown
- 2019-11-07 US US16/677,523 patent/US20200317644A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081097A patent/JP2020125348A/ja not_active Ceased
-
2021
- 2021-09-06 AR ARP210102479A patent/AR123441A2/es unknown
-
2022
- 2022-12-02 US US18/061,309 patent/US20230348438A1/en active Pending
-
2023
- 2023-05-02 JP JP2023075967A patent/JP2023087032A/ja not_active Ceased
-
2025
- 2025-01-06 JP JP2025000092A patent/JP2025039641A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008285481A (ja) | 2007-04-20 | 2008-11-27 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
Non-Patent Citations (1)
| Title |
|---|
| Ohsumi K et al., Bioorganic& Medicinal Chemistry Letters, 2003, 13(14), 2269-2272 (2003.7.21.) |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101989203B1 (ko) | 피라졸 화합물 및 그의 의약 용도 | |
| CN102838546B (zh) | 作为5-ht2a血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| WO2008059854A1 (en) | Piperidine derivatives or salts thereof | |
| CN107001259B (zh) | 作为taar配体的取代的氮杂环丁烷衍生物 | |
| KR20200062243A (ko) | 그리세오풀빈 화합물과 의약 용도 | |
| CN116322697A (zh) | 一种喹唑啉化合物及其药物组合物 | |
| TW201136926A (en) | Seven-membered ring compound and pharmaceutical use therefor | |
| TW202339706A (zh) | 含醯胺的ｌｏｎｐ１抑制劑化合物、用途及方法 | |
| HK1242309B (en) | Pyrazole compound and pharmaceutical use thereof | |
| HK1242309A1 (en) | Pyrazole compound and pharmaceutical use thereof | |
| NZ620977B2 (en) | Pyrazole compound and use thereof for medical purposes | |
| WO2004026832A1 (ja) | ウレア化合物およびその用途 | |
| TW201223952A (en) | Bicyclo-substituted pyrazolon azo derivatives pharmaceutcial salts, preparation process and pharmaceutical use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140225 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20170828 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20181019 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190320 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190607 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190607 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20220427 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220427 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240430 Start annual number: 6 End annual number: 6 |